Arcus Biosciences Inc (RCUS)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 150,000 | 201,000 | 156,000 | 185,000 | 127,000 | 184,000 | 230,000 | 238,000 | 206,000 | 218,000 | 273,000 | 549,000 | 148,000 | 179,432 | 320,482 | 390,260 | 173,415 | 221,849 | 285,185 | 67,326 |
| Short-term investments | US$ in thousands | 828,000 | 888,000 | 813,000 | 810,000 | 632,000 | 615,000 | 700,000 | 716,000 | 803,000 | 831,135 | 900,147 | 664,751 | 351,394 | 345,210 | 400,530 | 436,666 | 555,231 | 560,583 | 177,288 | 90,540 |
| Receivables | US$ in thousands | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 35,000 | 36,000 | 43,000 | 29,944 | 38,916 | 32,008 | 746,762 | 2,818 | 2,724 | 5,953 | 1,592 | 372 | 239 | — |
| Total current liabilities | US$ in thousands | 226,000 | 215,000 | 199,000 | 204,000 | 184,000 | 200,000 | 180,000 | 179,000 | 193,000 | 177,176 | 164,024 | 161,254 | 166,000 | 142,866 | 130,370 | 132,055 | 121,669 | 162,871 | 40,025 | 21,004 |
| Quick ratio | 4.35 | 5.09 | 4.89 | 4.90 | 4.15 | 4.02 | 5.36 | 5.53 | 5.45 | 6.09 | 7.39 | 7.73 | 7.51 | 3.69 | 5.55 | 6.31 | 6.00 | 4.81 | 11.56 | 7.52 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($150,000K
+ $828,000K
+ $5,000K)
÷ $226,000K
= 4.35
The quick ratio is a financial metric that provides insight into a company's short-term liquidity position by measuring its ability to cover immediate liabilities with its most liquid assets. For Arcus Biosciences Inc, the quick ratio fluctuated over the analyzed period, starting at a high of 11.56 in June 2020 and dropping to a low of 3.69 in September 2021.
The company's quick ratio generally stayed above 1, indicating that it had more than enough liquid assets to cover its current liabilities during most periods. This suggests that Arcus Biosciences Inc had a strong ability to meet its short-term obligations without relying heavily on inventory or other less liquid assets.
However, the downward trend in the quick ratio from September 2021 to December 2024, reaching a low of 4.02 in September 2023, raises potential concerns about the company's liquidity position. It may indicate a decrease in the availability of liquid assets relative to current liabilities during this period, which could pose challenges in meeting short-term financial obligations.
Investors and stakeholders should monitor Arcus Biosciences Inc's quick ratio closely to assess its ongoing ability to manage short-term liquidity needs effectively and address any potential liquidity risks that may arise in the future.
Peer comparison
Dec 31, 2024